Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC
Neal Shore, MD, FACS, outlines his treatment approach, which favors single agents over combination therapies, and incorporates bone-health drugs, vitamins, nutrition guidance, and exercise recommendations to support patients. While PSA remains a valuable biomarker in prostate cancer, he notes that ctDNA and aspects of MRD are gaining importance, although not yet widely adopted.
EP: 1.Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case
EP: 2.Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC
EP: 3.Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC
EP: 4.Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment
EP: 5.Addressing Unmet Needs and Final Perspectives on nmCRPC
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
